BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...not disclosed.   T-Cypher emerges from Orbit to develop TCR-based therapiesOxford-based T-Cypher Bio Ltd. separated from Orbit Discovery Ltd....
BioCentury | Nov 3, 2017
Company News

Zealand and Orbit in peptide discovery deal

...In September, gastrointestinal and metabolic disease company Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and Orbit Discovery (Oxford, U.K...
...Orbit Discovery Ltd., Oxford, U.K. Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), Glostrup, Denmark Business: Endocrine/Metabolic, Gastrointestinal Shannon Lehnbeuter Zealand Pharma A/S Orbit Discovery...
Items per page:
1 - 2 of 2
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...not disclosed.   T-Cypher emerges from Orbit to develop TCR-based therapiesOxford-based T-Cypher Bio Ltd. separated from Orbit Discovery Ltd....
BioCentury | Nov 3, 2017
Company News

Zealand and Orbit in peptide discovery deal

...In September, gastrointestinal and metabolic disease company Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and Orbit Discovery (Oxford, U.K...
...Orbit Discovery Ltd., Oxford, U.K. Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), Glostrup, Denmark Business: Endocrine/Metabolic, Gastrointestinal Shannon Lehnbeuter Zealand Pharma A/S Orbit Discovery...
Items per page:
1 - 2 of 2